Search research articles
Contact Us
Filters
Showing results (51-60 of 81) with videos related to
Page
of 9
Sort By:
Journal of Cellular Physiology
|
December 18, 2016
Human White Adipocytes Convert Into "Rainbow" Adipocytes In Vitro
Giulia Maurizi, Antonella Poloni, Domenico Mattiucci, et al.
Cancer Medicine
|
September 18, 2015
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence
Esther N Oliva, Michael Lauseker, Maria Antonietta Aloe Spiriti, et al.
Blood
|
October 25, 2013
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD
Attilio Olivieri, Michele Cimminiello, Paolo Corradini, et al.
European Journal of Haematology
|
May 25, 2010
Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion
Esther N Oliva, Maria Cuzzola, Francesco Nobile, et al.
Cancers
|
March 11, 2020
mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment
Antonio Vella, Elisabetta D'Aversa, Martina Api, et al.
Leukemia & Lymphoma
|
February 26, 2013
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy
Esther N Oliva, Roberto Latagliata, Carmelo Laganà, et al.
Annals of Hematology
|
September 18, 2012
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study
Esther Natalie Oliva, Maria Cuzzola, Maria Antonietta Aloe Spiriti, et al.
Cellular and Molecular Life Sciences : CMLS
|
February 27, 2023
MiR-422a promotes adipogenesis via MeCP2 downregulation in human bone marrow mesenchymal stem cells
Angelica Giuliani, Jacopo Sabbatinelli, Stefano Amatori, et al.
Blood
|
June 10, 2006
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma
Massimo Offidani, Laura Corvatta, Maria-Novella Piersantelli, et al.
Journal of Clinical Medicine
|
May 14, 2022
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?
Alessia Campagna, Daniela De Benedittis, Luana Fianchi, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 81) with videos related to
Sort By:
Page
of 9
Journal of Cellular Physiology
|
December 18, 2016
Human White Adipocytes Convert Into "Rainbow" Adipocytes In Vitro
Giulia Maurizi, Antonella Poloni, Domenico Mattiucci, et al.
Cancer Medicine
|
September 18, 2015
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence
Esther N Oliva, Michael Lauseker, Maria Antonietta Aloe Spiriti, et al.
Blood
|
October 25, 2013
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD
Attilio Olivieri, Michele Cimminiello, Paolo Corradini, et al.
European Journal of Haematology
|
May 25, 2010
Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion
Esther N Oliva, Maria Cuzzola, Francesco Nobile, et al.
Cancers
|
March 11, 2020
mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment
Antonio Vella, Elisabetta D'Aversa, Martina Api, et al.
Leukemia & Lymphoma
|
February 26, 2013
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy
Esther N Oliva, Roberto Latagliata, Carmelo Laganà, et al.
Annals of Hematology
|
September 18, 2012
Biological activity of lenalidomide in myelodysplastic syndromes with del5q: results of gene expression profiling from a multicenter phase II study
Esther Natalie Oliva, Maria Cuzzola, Maria Antonietta Aloe Spiriti, et al.
Cellular and Molecular Life Sciences : CMLS
|
February 27, 2023
MiR-422a promotes adipogenesis via MeCP2 downregulation in human bone marrow mesenchymal stem cells
Angelica Giuliani, Jacopo Sabbatinelli, Stefano Amatori, et al.
Blood
|
June 10, 2006
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma
Massimo Offidani, Laura Corvatta, Maria-Novella Piersantelli, et al.
Journal of Clinical Medicine
|
May 14, 2022
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?
Alessia Campagna, Daniela De Benedittis, Luana Fianchi, et al.
Page
of 9